Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ferric carboxymaltose to prevent postoperative anaemia and improve recovery after total knee arthroplasty
2022-001252-41Phase 4Completed
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ferric carboxymaltose in anaemia and total knee arthroplasty (TKA) (2 arms), sponsored by Centre Hospitalier Universitaire de Liège. Primary endpoint: Quality-of-Recovery-15 score at 15 days. Started Jun 2022; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
anaemiatotal knee arthroplasty (TKA)
Beyond the preview
Go deeper on 2022-001252-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001252-41.